lifitegrast (xiidra) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Lifitegrast (under brand name Xiidra) was approved as an ophthalmic solution for the treatment of the signs and symptoms of dry eye disease. Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1); a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). This LFA-1/ICAM-1 interaction is a key step in the inflammatory cascade that contributes to dry eye disease. Besides lifitegrast participates in phase II clinical trials for prevention of the signs and symptoms of allergic conjunctivitis.   NCATS

Chemistry

  • SMILES: CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1
  • InChIKey: JFOZKMSJYSPYLN-QHCPKHFHSA-N
  • Mol. Mass: 615.481
  • ALogP: 4.77
  • ChEMBL Molecule:
    lifitegrast  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$6.8248 - $9.4666
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(2s)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid | lifitegrast | l-phenylalanine, n-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)- | sar 1118 | sar-1118 | sar 1118-023 | shp606 | shp-606 | xiidra

Organizations (29)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Dry Eye Syndromes

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Conjunctivitis, Allergic (Phase 2)

Contact Lenses (Phase 4)

Corneal Diseases (Phase 4)

Dry Eye Syndromes ()

Graft vs Host Disease (Early Phase 1)

Inflammation (Phase 4)

Keratoconjunctivitis Sicca (Phase 4)

Macular Edema (Phase 1)

Vision, Ocular (Phase 4)

Vitreous Body (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue